Stratatech Receives another NIH Grant

Madison, Wis. - Stratatech Corporation, a UW spin-off company, has received a $168,000 Phase I SBIR Grant from the National Institute on Aging, for the development of cell-based gene therapy products for the treatment of chronic skin wounds such as diabetic, venous stasis and pressure ulcers, which are particularly problematic for the aged population.

It is estimated that in the United States alone, millions of people annually suffer from chronic ulcers, and that number is growing as the population ages. Chronic ulcers often are complicated by poor vascularization, which contributes to poor wound healing. Stratatech is working to develop human skin substitutes that will stimulate the in-growth of blood vessels into chronic wounds, facilitating their healing.